antibiot
greatli
reduc
mortal
morbid
associ
bacteri
infect
develop
effect
antivir
proceed
much
slowli
hepat
c
viru
hcv
infect
remain
worldwid
health
problem
vaccin
current
avail
number
small
molecul
inhibitor
viral
encod
enzym
show
promis
clinic
trial
approv
us
fda
cure
hcv
gener
requir
multipl
agent
differ
mechan
action
due
develop
viral
resist
viral
escap
result
high
error
rate
viral
rnadepend
rna
polymeras
allow
rapid
explor
sequenc
space
creat
myriad
quasispeci
may
includ
mutat
confer
resist
given
drug
small
interf
rna
sirna
cousin
small
hairpin
rna
shrna
two
advantag
small
molecul
drug
suggest
potenti
solut
viral
resist
problem
first
potenti
target
conserv
undrugg
sequenc
anywher
viral
genom
includ
noncod
sequenc
second
multipl
small
sirna
shrna
combin
foil
abil
viru
escap
singlesit
mutat
chronic
hcv
infect
repres
common
form
diseas
also
attract
diseas
target
rnai
cours
infect
slow
thu
plenti
time
biolog
rna
interfer
take
place
contrast
rapid
viral
infect
viral
replic
may
outrun
treatment
requir
hour
take
full
effect
review
describ
develop
new
class
rna
interfer
rnai
effector
short
shrna
sshrna
hcv
drug
sshrna
design
target
conserv
intern
ribosom
entri
site
ire
element
hcv
genom
one
highli
conserv
region
viral
genom
short
length
around
nt
distinguish
tradit
shrna
potenc
mechan
action
hcv
singlestrand
positivesens
rna
viru
common
bloodborn
rna
viru
estim
million
person
current
infect
unit
state
million
worldwid
total
million
peopl
newli
infect
year
armstrong
et
al
alter
et
al
shepard
et
al
ray
kim
approxim
human
immunodefici
viru
hiv
infect
person
unit
state
coinfect
hcv
http
wwwcdcgovncidoddiseaseshepatitisc
hcv
recogn
major
caus
endstag
liver
diseas
liver
cancer
hcv
case
lead
outcom
cirrhosi
case
lead
indic
liver
transplant
western
world
shepard
et
al
chronic
liver
diseas
rank
tenth
lead
caus
death
unit
state
hcv
estim
account
case
mortal
relat
hcv
infect
death
liver
failur
hepatocellular
carcinoma
expect
increas
next
two
decad
deufficburban
et
al
six
major
genotyp
hcv
standard
treatment
combin
pegyl
interferon
ifn
ribavirin
effect
patient
depend
genotyp
efficaci
around
patient
infect
hcv
genotyp
compris
nearli
case
western
hemispher
although
success
rate
improv
addit
newli
approv
proteas
inhibitor
standard
treatment
respons
rate
coinfect
patient
lower
estim
torriani
et
al
interferon
associ
sever
advers
effect
includ
flulik
symptom
hematolog
abnorm
depress
patient
complianc
poor
estim
patient
refus
treatment
consid
incid
hcv
increas
worldwid
within
year
death
hcv
hiv
predict
center
diseas
control
safer
efficaci
hcv
drug
urgent
need
deufficburban
et
al
law
et
al
salomon
et
al
hcv
drug
candid
develop
divid
target
viru
directli
directact
antivir
daa
agent
affect
host
target
ronn
sandstrom
liuyoung
kozal
beaulieu
daa
includ
small
molecul
well
ribozym
antisens
oligonucleotid
aso
decoy
rna
rna
aptam
sirna
shrna
hosttarget
agent
includ
small
molecul
cyclophilin
inhibitor
antifibrot
agent
antibodi
modifi
interferon
improv
pharmacokinet
oligonucleotid
complementari
requir
host
factor
lanford
et
al
mention
high
genet
divers
rapid
mutat
turnov
rate
hcv
new
particl
produc
per
day
error
rate
mutat
per
nucleotid
per
genom
replic
result
rapid
emerg
viral
resist
mani
singl
daa
okamoto
et
al
neumann
et
al
ogata
et
al
sarrazin
zeuzem
instanc
although
clinic
studi
show
use
proteas
inhibitor
combin
pegyl
pegifn
ribavirin
increas
rate
sustain
viral
respons
svr
least
compar
pegifn
ribavirin
alon
patient
infect
hcv
genotyp
exist
viral
variant
reduc
suscept
observ
deufficburban
et
al
sarrazin
zeuzem
robinson
et
al
oligonucleotidebas
daa
sirna
shrna
gener
best
efficaci
potenc
vitro
well
anim
ronn
sandstrom
mchutchison
et
al
addit
abil
rnai
effici
limit
viral
replic
target
multipl
gene
andor
sequenc
simultan
make
attract
therapeut
approach
limit
emerg
resist
mutant
sirna
vectorexpress
shrna
shown
significantli
decreas
hcv
rna
replic
protein
express
cell
cultur
well
anim
system
watanab
et
al
randal
rice
kapadia
et
al
wilson
et
al
yokota
et
al
seo
et
al
takigawa
et
al
prabhu
et
al
sen
et
al
kanda
et
al
recent
synthet
shrna
gain
attent
discuss
rna
interfer
rnai
play
central
role
regul
eukaryot
gene
express
associ
variou
biolog
process
rang
develop
cell
homeostasi
diseas
particularli
cancer
often
associ
dysregul
particular
mirna
shenouda
alahari
mechan
rnai
complex
involv
altern
pathway
filipowicz
siomi
siomi
doublestrand
rna
dsrna
molecul
recogn
process
one
rnase
iiifamili
enzym
hammond
et
al
zamor
et
al
bernstein
et
al
primari
transcript
encod
microrna
primir
process
nucleu
microprocessor
complex
individu
hairpin
export
cytoplasm
cytoplasm
dsrna
longer
bp
includ
hairpin
process
dicer
doublestrand
sirna
whose
strand
nucleotid
nt
length
dicer
contain
paz
domain
bind
specif
end
singlestrand
rna
two
rnase
iii
domain
possess
catalyt
cleavag
activ
distanc
paz
domain
activ
site
rnase
iii
domain
provid
molecular
ruler
correspond
length
sirna
duplex
jinek
doudna
cleavag
product
dicer
characterist
termini
monophosph
group
end
twonucleotid
overhang
end
macra
doudna
srna
whether
gener
dice
precursor
rna
introduc
outsid
cell
load
rnainduc
silenc
complex
risc
contain
protein
argonaut
ago
famili
elbashir
et
al
lee
et
al
pham
et
al
tomari
et
al
b
jinek
doudna
ago
protein
contain
paz
middl
mid
piwi
domain
bind
sirna
ago
aid
presenc
phosphat
group
dinucleotid
overhang
termini
dicer
overhang
bind
paz
domain
ago
phosphat
group
bind
pocket
interfac
mid
domain
piwi
domain
jinek
doudna
four
human
ago
thought
one
abl
mediat
cleavag
target
mrna
hammond
et
al
okamura
et
al
meister
et
al
rand
et
al
liu
et
al
song
et
al
riva
et
al
render
guid
antisens
strand
sirna
avail
pair
target
passeng
strand
must
remov
select
strand
remov
retain
thought
larg
govern
asymmetri
thermodynam
profil
sirna
duplex
termini
schwarz
et
al
khvorova
et
al
riscload
complex
contain
dsrna
bind
protein
trbp
along
dicer
load
sirna
duplex
cleav
slice
passeng
sens
strand
posit
opposit
nt
guid
strand
facilit
dissoci
andor
degrad
ye
et
al
result
passengerstrand
fragment
loss
passeng
strand
complex
produc
activ
risc
anchor
phosphat
group
bind
pocket
ago
essenti
distanc
determin
posit
cleavag
site
passeng
strand
passengerstrand
cleavag
also
found
process
microrna
mirna
diederich
haber
passengerstrand
slice
block
chemic
modif
mismatch
two
strand
sirna
slower
altern
pathway
dissoci
destroy
passeng
strand
possibl
via
atpdepend
helicas
rna
helicas
yield
activ
risc
matranga
et
al
leuschner
et
al
miyoshi
et
al
kraynack
baker
robb
rana
rand
et
al
risc
use
bound
singlestrand
rna
molecul
guid
search
resid
popul
messeng
rna
mrna
complementari
sequenc
eventu
cleav
transcript
therebi
downregul
express
target
gene
hammond
et
al
dorsett
tuschl
kim
rossi
elbashir
et
al
nykanen
et
al
martinez
et
al
current
favor
model
target
recognit
cleavag
follow
target
bind
seed
region
half
guid
sequenc
base
pair
proce
toward
end
result
end
guid
strand
dissoci
paz
domain
lead
conform
chang
posit
activ
site
cleavag
site
target
filipowicz
tomari
zamor
posit
scissil
phosphat
group
target
mrna
similar
passeng
strand
ie
nt
group
guid
strand
mismatch
nucleotid
prevent
slice
activ
jinek
doudna
endogen
rnai
machineri
exploit
advanc
wide
rang
studi
involv
gene
function
analysi
pathway
map
drug
target
valid
interact
natt
dorsett
tuschl
iorn
et
al
new
understand
rnai
regul
gene
express
also
lead
rapid
develop
rnaibas
therapeut
especi
area
viral
diseas
exampl
rnai
approach
target
viral
gene
includ
hiv
influenza
hepat
b
c
virus
tabl
respiratori
syncyti
viru
polio
viru
sar
coronaviru
alphavirus
marburg
dengu
fever
virus
shown
limit
viral
replic
cell
cultur
case
anim
rossi
et
al
barik
bitko
watanab
et
al
arbuthnot
et
al
seyhan
et
al
gitlin
et
al
fowler
et
al
haasnoot
et
al
number
sirna
drug
candid
clinic
trial
castanotto
rossi
moreov
mechanist
studi
dsrnasirnamirna
process
dicer
also
led
develop
algorithm
effici
target
select
chemic
modif
improv
specif
function
longev
new
design
rnai
trigger
dicer
substrat
ssirna
etc
benefit
basic
appli
research
bolcatobellemin
et
al
collingwood
et
al
shrna
consist
larg
pair
antisens
sens
sequenc
connect
loop
unpair
nucleotid
duplex
stem
typic
bp
either
fulli
pair
mirnastyl
intern
mismatch
loop
commonli
use
vectorexpress
shrna
silva
et
al
stegmeier
et
al
boudreau
et
al
although
target
site
select
critic
silenc
activ
structur
design
shrna
also
play
signific
role
appropri
design
shrna
least
activ
sirna
target
site
although
relationship
sirna
extens
examin
rna
duplex
overhang
end
strand
wide
use
hand
studi
effect
hairpin
structur
efficaci
target
silenc
factor
involv
shrna
design
loop
size
sequenc
stem
length
presenc
intern
mismatch
singlestrand
overhang
whether
express
synthet
directli
deliv
sirna
stem
length
determin
whether
molecul
substrat
dicer
context
vector
express
fulli
match
shrna
compar
shrna
contain
intern
mismatch
sequenc
alter
passeng
arm
fulli
match
shrna
found
potent
li
et
al
boudreau
et
al
loop
almost
size
nucleotid
brummelkamp
et
al
found
express
shrna
loop
provid
better
target
knockdown
similar
shrna
loop
brummelkamp
et
al
efficaci
seen
express
shrna
depend
express
level
well
design
paramet
hinton
et
al
kawasaki
et
al
zhou
et
al
investig
design
paramet
alon
sever
group
examin
impact
structur
chang
synthet
hairpin
found
length
stem
loop
affect
efficaci
li
et
al
report
context
loop
shrna
stem
silenc
target
gene
express
effici
stem
shrna
loop
outperform
shrna
longer
stem
includ
shrna
loop
li
et
al
group
found
context
loop
shrna
somewhat
potent
similar
sirna
shrna
less
potent
shrna
sirna
test
vlassov
et
al
posit
antisens
sequenc
within
hairpin
also
affect
shrna
efficaci
shrna
often
design
sens
sequenc
end
hairpin
righthand
loop
rtype
shrna
vlassov
et
al
li
et
al
fig
harborth
et
al
report
shrna
antisens
sequenc
end
hairpin
lefthand
loop
ltype
shrna
show
compar
silenc
efficaci
r
shrna
stem
length
nt
harborth
et
al
howev
stem
length
shorten
bp
loop
much
less
potenc
found
r
shrna
wherea
l
shrna
retain
potenc
compar
shrna
stem
similar
result
obtain
anoth
group
shrna
mcmanu
et
al
togeth
result
suggest
shrna
may
process
differ
shrna
bp
longer
major
differ
longer
shrna
r
l
type
process
dicer
gener
sirna
contrast
shrna
found
dicer
substrat
siola
et
al
mcmanu
et
al
distinguish
shrna
fewer
base
pair
longer
dicer
substrat
shrna
design
former
short
shrna
sshrna
shorten
sens
sequenc
synthet
lsshrna
end
nt
maintain
length
antisens
arm
nt
significantli
reduc
gene
silenc
activ
suggest
duplex
structur
end
antisens
sequenc
import
fig
ge
et
al
howev
overal
length
duplex
shorter
bp
sshrna
stem
virtual
potent
similar
version
fig
shorten
stem
nt
strand
connect
uu
might
form
stem
guuc
loop
result
somewhat
lower
activ
sshrna
nt
arm
duplex
littl
activ
indic
potent
silenc
activ
requir
hairpin
duplex
length
least
bp
interestingli
sshrna
stem
bp
consist
antisens
sequenc
connect
directli
sens
sequenc
show
similar
potenc
compar
parent
molecul
stem
uu
linker
examin
relationship
sshrna
may
differ
dicersubstr
shrna
group
undertook
extens
mechanist
studi
sshrna
target
three
partial
overlap
sequenc
within
intern
ribosom
entri
site
ire
hcv
ge
et
al
b
dalla
et
al
two
target
site
ltype
sshrna
show
significantli
higher
potenc
rtype
third
littl
differ
two
hairpin
type
unlik
rsshrna
loop
size
nt
greater
optim
vlassov
et
al
li
et
al
lsshrna
potent
loop
size
small
nt
larger
nt
fig
lsshrna
bp
uu
loop
slightli
potent
correspond
sirna
target
region
loop
sequenc
appear
affect
sshrna
activ
sinc
three
differ
loop
sequenc
includ
one
deriv
microrna
gave
result
howev
nucleotid
adjac
loop
may
affect
activ
affect
actual
size
loop
exampl
cg
base
pair
next
uu
loop
pair
result
actual
loop
jucker
pardi
wherea
base
pair
au
ua
strain
loop
may
keep
unpair
result
loop
auuu
uuua
base
studi
involv
chemic
modif
condit
dicerknockout
cell
ago
immunoprecipit
conclud
dalla
et
al
lsshrna
uu
loop
natur
quit
resist
rnase
cleavag
ge
et
al
requir
passengerarm
cleavag
maxim
activ
loop
remain
intact
activ
risc
guid
strand
break
base
pair
truncat
passeng
strand
allow
pair
target
passengerstrand
slice
need
appar
facilit
open
guidepasseng
duplex
lsshrna
guid
sequenc
side
loop
end
guid
sequenc
immedi
avail
phosphoryl
bind
mid
pocket
rsshrna
hand
requir
larger
loop
full
activ
loop
must
cleav
nucleas
creat
termin
phosphat
end
guid
strand
see
fig
case
passengerarm
slice
less
import
cleavag
loop
facilit
remov
passeng
strand
activ
risc
wherea
presenc
short
flank
sequenc
gener
enhanc
effici
gene
knockdown
r
shrna
siola
et
al
vlassov
et
al
presenc
absenc
overhang
rel
littl
effect
silenc
abil
lsshrna
fig
appear
loop
gener
cleav
lsshrna
stem
open
loop
avail
bind
paz
domain
dalla
et
al
synthet
shrna
usual
simpli
dissolv
buffer
prior
vitro
vivo
use
whether
shrna
form
expect
hairpin
structur
solut
frequent
ignor
found
synthet
shrna
irrespect
stem
length
loop
size
l
vs
r
loop
orient
form
dimer
even
oligom
ge
et
al
dimer
hairpin
rna
also
document
retrovir
rna
trna
artifici
rna
hairpin
sun
et
al
propens
hairpin
rna
dimer
depend
loop
size
sequenc
concentr
well
handl
bernacchi
et
al
liu
et
al
shrna
heat
quickli
cool
ice
bath
snap
cool
dimer
elimin
ge
et
al
interestingli
sshrna
show
effici
target
knockdown
heatingsnap
cool
procedur
even
sshrna
predominantli
dimer
treatment
suggest
dimer
certain
sshrna
function
molecul
process
util
rnai
machineri
similar
effici
monom
howev
presenc
long
duplex
region
dimer
provok
immun
stimul
heatingcool
procedur
greatli
reduc
immun
stimul
tabl
like
rna
shrna
nonid
drug
due
suscept
degrad
nucleas
tendenc
sequenc
structur
featur
caus
unwant
immun
stimul
studi
effect
dna
phosphorothio
modif
variou
posit
stem
loop
overhang
found
place
nucleotid
loop
altern
nucleotid
passeng
arm
leav
unmodifi
window
nt
slicer
site
provid
significantli
greater
stabil
human
serum
fig
abrog
induct
innat
immun
system
ge
et
al
seen
tabl
two
sshrna
structur
differ
sequenc
differ
immunostimulatori
properti
blunt
sshrna
particularli
effici
induc
rigi
case
howev
render
nonstimulatori
block
recognit
pattern
recognit
sensor
rigi
modif
essenti
effect
potenc
place
modif
posit
guid
arm
slicer
site
passeng
arm
reduc
efficaci
phosphorothio
modif
found
induc
interferonbeta
cell
synthet
sshrna
highli
potent
rnai
effector
properli
design
rsshrna
requir
longer
loop
least
nt
presenc
dinucleotid
overhang
maxim
efficaci
li
et
al
vlassov
et
al
siola
et
al
contrast
lsshrna
least
one
test
possess
loop
short
nt
even
direct
connect
two
strand
uu
loop
particularli
effect
overhang
essenti
mani
activ
lsshrna
antisens
sens
sequenc
either
nt
modif
everi
nucleotid
passeng
arm
except
around
slicer
site
help
increas
stabil
nucleas
eg
found
serum
minim
immun
stimul
particularli
bluntend
sshrna
cool
step
immedi
prior
use
advis
elimin
dimer
